Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase Ⅱ ,Open-label ,Single Institution Study to Investigate the Efficacy and Safety of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04606108
• Other study ID #: OBU-GD1-BB-STS-II-003
• Status: Recruiting
• Phase: Phase 2
• Start date: October 19, 2020
• Est. completion date: March 19, 2024

Study information

• Verified date: October 2020
• Source: Sun Yat-sen University
• Contact: Jin Wang, MD
• Phone: 020-87343910
• Email: wangjinr[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a open-lable , single arm，single center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with Liposome doxorubicin and Ifosfamide in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Description:

In this study, eligible subject will be enrolled into study arm to accept study treatment. Treatment cycles of chemotherapy will be at most 8 cycles which will be decided by investigators. Objective response rate will be the primary outcome measures.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 62
• Est. completion date: March 19, 2024
• Est. primary completion date: October 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age 14 to 65 year old;

2. Eastern Cooperative Oncology Group performance status 0-1;

3. The high-risk soft tissue sarcoma of limbs or trunk (FNCLCC grade 3 or FNCLCC grade2 but imaging evaluation showed that it was more than 50% necrosis; more than 5cm; deep tumor), including synovial sarcoma, undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma, pleomorphic rhabdomyosarcoma, round cell /Myxiod liposarcoma,Malignant peripheral nerve sheath tumors, etc;

4. Patients with soft tissue sarcoma who are ready for neoadjuvant chemotherapy need to meet the following conditions:

1. According to the evaluation, the patients who received neoadjuvant chemotherapy can achieve standard resection of tumor

2. If important structures (blood vessels and nerves) are involved, radical operation cannot be performed

5. Having measurable lesion according to RECIST 1.1

6. Life expectancy >3 months

7. Patients must have adequate organ function

8. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential must have a negative pregnancy test = 72 hours prior to Day 1 of study

9. Voluntary informed consent , joining the study with good compliance

Exclusion Criteria:

• 1. pregnant or lactating women 2. Known history of hypersensitivity to any components of the camrelizumab formulation, or other antibody formulation.

3. Active central nervous system (CNS) metastases with clinical symptoms , including cerebral edema, steroid requirement, or progressive disease.

4. Patients with other malignant tumor within 5 years , except cured skin basal cell carcinoma, cervical carcinoma and Papillary carcinoma of thyroid.

5. Clinically significant cardiovascular diseases 6. Have received any of the following treatments:

1. Patients have had prior treatment with PD-1/PD-L1 or CTLA-4 antagonists.

2. Received any study drug within 4 weeks prior to the first study drug administration.

3. Enroll in another clinical study, unless it is an observational (non-interventional) clinical study or an intervention follow-up study.

4. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids.

5. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. Note: corticosteroids used for the allergy and nausea, vomiting are allowed. Inhaled or topical use of steroids and adrenocorticosteroid replacement in doses greater than 10mg/ day is permitted in the absence of active autoimmune disease.

6. Patients who have received a live vaccine within 30 days prior to the first study drug administration.

7. Major surgery or major trauma within 4 weeks of first study drug administration. Left ventricular ejection fraction (LVEF) is more than 60% .

7. Severe infection occurred within 4 weeks before the first study drug administration (CTC AE > grade 2) 8. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. Stable dose of insulin for type 1 diabetes.

9. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or organ transplantation and bone marrow transplantation.

10. Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc.

11. History of active pulmonary tuberculosis infection, or with a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or with a history of active pulmonary tuberculosis infection prior to 1 year but without formal treatment.

12. Active hepatitis (transaminase does not meet the inclusion, hepatitis B virus (HBV) DNA =104 /ml or hepatitis C virus (HCV) RNA=103 /ml or higher); Chronic hepatitis B virus carriers who HBV DNA<2000 IU/ml(<104/ml), must receive anti-viral treatment throughout the study.

13. Known history of psychotropic substance abuse, alcohol abuse and drug abuse.

14. The investigators did not think the participants were suitable for inclusion.

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Camrelizumab in Combination With Neoadjuvant Chemotherapy
camrelizumab in combination with Liposome doxorubicin and Ifosfamide

Locations

Country	Name	City	State
China	Sun Yat-sen University cancer center	GuangZhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Sun Yat-sen University	Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	ORR	24 months
Secondary	2 years Overall Survival (OS) rate	The percentage of patients overall survival in 2 years	24 months
Secondary	2 years Progression-free survival (PFS) rate	The percentage of patients Progression-free survival in 2 years	24 months
Secondary	Adverse Events (AEs)	All adverse event/Serious adverse event that occurred during the study period according to CTCAE	24 months